Abstract: Methods of inhibiting reactive oxygen species production by neutrophils or treating neutrophil-mediated inflammation in a subject by contacting the neutrophils with or administering an agent selected from a cyclin dependent kinase 4 (CDK4) inhibitor, a cyclin dependent kinase 6 (CDK6) inhibitor, an epidermal growth factor receptor (EGFR) inhibitor, a proto-oncogene tyrosine-protein kinase Src (SRC) inhibitor and a sodium (Na) channel blocker are provided. Pharmaceutical compositions comprising a nanoparticle, the agent and a neutrophil targeting peptide are also provided.
Type:
Application
Filed:
July 28, 2022
Publication date:
October 31, 2024
Applicants:
IMMUNYX PHARMA LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., Hadasit Medical Research Services and Development Ltd.
Abstract: A composition of matter is provided comprising a devitalized, acellular tissue-derived scaffold seeded with differentiated cells, particularly pancreatic islet cells, wherein the cells can maintain cell-specific function or structure in culture on the scaffold. Methods of generating same and uses thereof are also provided.
Type:
Application
Filed:
July 11, 2024
Publication date:
October 31, 2024
Applicant:
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LT
Abstract: The disclosure concerns viscous or gelled delivery systems based on oily nano-domains dispersed in a viscosified/gelled continuous aqueous phase, and suitable for prolonged and/or sustained topical delivery of various active compounds.
Type:
Application
Filed:
June 27, 2024
Publication date:
October 24, 2024
Applicants:
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., LYOTROPIC DELIVERY SYSTEMS LTD
Abstract: The present invention provides oligonucleotides capable of binding to and modulating the splicing of the pre-mRNA of the CFTR gene, including compositions comprising the oligonucleotides, and uses thereof, such as for suppressing the inclusion of a cryptic exon between exon 22 and 23 as a result of the mutation 3849+10 Kb C-to-T, optionally in combination with additional CF therapeutics.
Type:
Application
Filed:
July 7, 2024
Publication date:
October 24, 2024
Applicants:
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., SpliSense Ltd.
Inventors:
Bat Sheva KEREM, Efrat OZERI-GALAI, Yifat OREN, Ofra BARCHAD-AVITZUR
Abstract: Natural killer (NK) cell killing of various tumors is inhibited in the presence of ligands of TIGIT, an inhibitory receptor present on all human NK cells and on various T cells. Monoclonal antibodies that recognize TIGIT and inhibit its suppressive activity on T-cells are provided as well as pharmaceutical compositions comprising them and methods for their use in cancer immunotherapy and in diagnosis and treatment of immune disorders.
Type:
Grant
Filed:
February 5, 2021
Date of Patent:
October 22, 2024
Assignees:
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., UNIVERSITY OF RIJEKA FACULTY OF MEDICINE
Inventors:
Ofer Mandelboim, Noa S. Kaynan, Pinchas Tsukerman, Stipan Jonjic
Abstract: The invention provides compounds and uses thereof in the treatment and prevention of diseases and conditions associate with or aggravated by impaired mitophagy or oxidative stress, and methods of their preparation.
Type:
Application
Filed:
July 5, 2022
Publication date:
October 17, 2024
Applicant:
Yissum Research Development Company of The Hebrew University of Jerusalem Ltd.
Abstract: Haploid human embryonic stem cells and cell lines, haploid multipotent human cells, and haploid differentiated human cells are provided. In addition, methods of making and using the haploid human cells are provided.
Type:
Grant
Filed:
December 15, 2020
Date of Patent:
September 17, 2024
Assignees:
New York Stem Cell Foundation, Inc., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
Inventors:
Dietrich M. Egli, Nissim Benvenisty, Ido Sagi
Abstract: The invention relates to a nasally administrable composition comprising at least one active substance in magnesium-containing vesicular carrier, said carrier comprising glycol, phospholipids, water and at least one magnesium source. Methods for nasal administration of the composition, for example, for pain relief, are also provided.
Type:
Grant
Filed:
June 9, 2022
Date of Patent:
August 20, 2024
Assignee:
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD
Abstract: A composition of matter is provided comprising a devitalized, acellular tissue-derived scaffold seeded with differentiated cells, particularly pancreatic islet cells, wherein the cells can maintain cell-specific function or structure in culture on the scaffold. Methods of generating same and uses thereof are also provided.
Type:
Grant
Filed:
September 7, 2018
Date of Patent:
August 13, 2024
Assignee:
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
Abstract: The present invention provides a method of treating a disease or disorder characterized by electro-mitochondrial desynchronization in a subject in need thereof, comprising confirming the disease or disorder is characterized by electro-mitochondrial desynchronization in the subject and administering an agent that modulates mitochondrial calcium concentration and/or increases mitochondrial calcium channel activity in a tissue of the disease or disorder in the subject. Multichambered cardiac organoids comprising cardiomyocytes and endothelial cells and at least two chambers beating in synchrony are provided. Further provided are methods of using the multichambered cardiac organoid, methods of producing a cardiac organoid. Systems for making measurements within cellular aggregates or tissues and the use of same for testing therapeutic agents is also provided.
Type:
Application
Filed:
March 7, 2024
Publication date:
August 8, 2024
Applicant:
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
Inventors:
Yaakov NAHMIAS, Mohammad GHOSHEH, Avner EHRLICH
Abstract: The present invention relates to a method for forming a protective coating on a plant tissue by applying a first aqueous solution containing a crosslinking agent to a postharvest plant matter having an external surface that includes a first segment which is covered by natural skin and a second segment which has an exposed surface, wherein the first aqueous solution is applied at least upon the exposed surface of the second segment of the postharvest plant matter; and subsequently applying a second aqueous solution comprising a polysaccharide which is susceptible to crosslinking by the crosslinking agent at least upon the exposed surface of the second segment of the postharvest plant matter, thereby forming a protective coating on the exposed surface of the second segment of the postharvest plant matter due to crosslinking of the polysaccharide by the crosslinking agent.
Type:
Application
Filed:
April 2, 2024
Publication date:
July 25, 2024
Applicant:
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd
Abstract: A system is presented for non-invasive monitoring one or more blood conditions of a media in a region of interest. The system comprises: a sensor device comprising at least one antenna sensor configured to be placed in the vicinity of the media and configured and operable to generate antenna beams of different frequencies in a frequency range of about 100 MHz to 90 GHz, receive radiation responses from the medium, and generate corresponding sensing data; and a control unit configured to receive and process said sensing data to determine a dielectric spectrum of the media indicative of dielectric response of cytoplasm containing cells (red blood cells) in the media and determine one or more blood conditions.
Type:
Grant
Filed:
March 22, 2017
Date of Patent:
July 23, 2024
Assignee:
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
Inventors:
Yuri Feldman, Paul Ben-Ishai, Saul Yedgar, Gregory Barshtein, Andreas Caduff
Abstract: The present invention is directed to methods for determining an autism spectrum condition in a subject. Further provided is a kit suitable for determining an autism spectrum condition.
Type:
Application
Filed:
May 25, 2022
Publication date:
July 18, 2024
Applicant:
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
Abstract: The invention relates to a block co-polymer film having different morphologies within said film, uses thereof and processes for its preparation.
Type:
Grant
Filed:
July 29, 2019
Date of Patent:
July 2, 2024
Assignee:
Yissum Research Development Company of The Hebrew University of Jerusalem Ltd.
Inventors:
Roy Shenhar, Elisheva Michman, Marcus Muller
Abstract: A solid polymer composition or object or composite is provided, which includes a polymeric material and at least one agent having an antimicrobial functionality.
Type:
Application
Filed:
April 17, 2022
Publication date:
June 27, 2024
Applicants:
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., CARMEL OLEFINS LTD.
Inventors:
Meital RECHES, Michael GISHBOLINER, Koranit SHLOSMAN BALASHA, Rotem SHEMESH
Abstract: A method of detecting iron-related entities in a region of interest, is disclosed. The method may comprise: receiving at least two Magnetic Resonance Imaging (MRI) signals from each of at least two different locations in the region of interest; calculating at least four MRI parameters from the MRI signals; and determining a presence of at least two different iron-related entities in the region of interest based on the at least four MRI parameters.
Type:
Application
Filed:
April 13, 2022
Publication date:
June 20, 2024
Applicant:
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
Abstract: The invention provides a class of polymeric materials being ABA tri-block or AB di-block, comprised of biodegradable segments and poly(propylene oxide) (PPO) segment and uses thereof.
Type:
Grant
Filed:
December 31, 2015
Date of Patent:
June 11, 2024
Assignee:
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
Abstract: The present invention provides pyrazole derivatives, e.g., a compound of Formula (I), and their uses in methods of treating malignant disease and disorders and methods for treating inflammatory diseases and disorders.
Type:
Grant
Filed:
July 26, 2021
Date of Patent:
June 4, 2024
Assignee:
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd
Inventors:
Dansu Li, Irit Snir-Alkalay, Joseph P. Vacca, Yinon Ben-Neriah, Avanthika Venkatachalam